Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peripheral Neuropathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    458 result(s) found for: Peripheral Neuropathy. Displaying page 8 of 23.
    EudraCT Number: 2017-004707-43 Sponsor Protocol Number: PP06489 Start Date*: 2018-08-09
    Sponsor Name:PledPharma AB
    Full Title: A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in th...
    Medical condition: Chemotherapy induced peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10079545 Chemotherapy induced peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) GB (Completed) ES (Temporarily Halted) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003865-11 Sponsor Protocol Number: NEOD001-CL002 Start Date*: 2015-11-27
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai...
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001320-36 Sponsor Protocol Number: HM12/10191 Start Date*: 2012-08-28
    Sponsor Name:University of Leeds
    Full Title: A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma.
    Medical condition: multiple myeloma at the first relaspe of primary refractory disease stage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002731-32 Sponsor Protocol Number: 1208.34 Start Date*: 2008-10-20
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A 12 weeks open label two parallel groups study to assess the efficacy of orally administered duloxetine 60 mg and 120 mg per day on treatment outcomes in patients with diabetic peripheral neuropat...
    Medical condition: Painful diabetic polyneuropathy according to ICD-10 with or without co-morbid Major Depressive Disorder according to ICD-10 (F32 and F33).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012685 Diabetic polyneuropathy LLT
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004876-37 Sponsor Protocol Number: PL37-C03-2013 Start Date*: 2014-03-31
    Sponsor Name:Pharmaleads SA
    Full Title: A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pa...
    Medical condition: Neuropathic pain develops as a result of damage to, or dysfunction of, the system that normally signals pain. It may arise from a heterogeneous group of disorders that affect the peripheral and cen...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002718-17 Sponsor Protocol Number: IMVT-1401-2401 Start Date*: 2023-06-19
    Sponsor Name:Immunovant Sciences, GmbH
    Full Title: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077384 Chronic inflammatory demyelinating polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002707-18 Sponsor Protocol Number: EFFECT Start Date*: 2012-11-14
    Sponsor Name:FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS
    Full Title: EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancer
    Medical condition: Patients aged 65 years or older with histologically or cytologically confirmed breast cancer, locally recurrent and/or metastatic; any estrogen/progesterone receptor status; HER2 receptor negative ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000528-17 Sponsor Protocol Number: IAEA-HypoX Start Date*: 2012-06-05
    Sponsor Name:Department of Experimental Clinical Oncology
    Full Title: A randomized multicenter study of accelerated fractionated radiotherapy with or without the hypoxic radiosensitizer nimorazole in the treatment of squamous cell carcinoma of the head and neck
    Medical condition: Squamous Cell Carcinoma of the Head and Neck region
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001117-34 Sponsor Protocol Number: APL-B-013-02 Start Date*: 2004-10-13
    Sponsor Name:Pharma Mar S.A.
    Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.
    Medical condition: Aggressive non-Hodgkin’s Lymphoma.For aggressive NHL patient cure is still the target of therapy and a CR is a prerequisite to achieve this goal. Salvage therapy needs more aggressive experimental ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002758-31 Sponsor Protocol Number: ECD01 Start Date*: 2006-12-22
    Sponsor Name:EPOPLUS GmbH & Co.KG
    Full Title: A randomized, double-blind, multi-centre, placebo-controlled, parallel-group study to examine the efficacy and safety of low dose Epoetin beta on wound healing in diabetes patients with foot ulcer
    Medical condition: wound healing in diabetes patients with foot ulcer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10048037 Wound healing disturbance of LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001200-20 Sponsor Protocol Number: CSET 1287 Start Date*: 2007-06-01
    Sponsor Name:Institut Gustave Roussy
    Full Title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer
    Medical condition: adenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003382-16 Sponsor Protocol Number: RMC1 Start Date*: 2005-11-10
    Sponsor Name:Guy's & St Thomas's NHS Foundation Trust [...]
    1. Guy's & St Thomas's NHS Foundation Trust
    2. King's College London
    Full Title: Pilot randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial).
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002792-41 Sponsor Protocol Number: Fx-005 Start Date*: 2006-10-30
    Sponsor Name:FoldRx Pharmaceuticals Limited
    Full Title: Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study
    Medical condition: Familial Amyloid Polyneuropathy (FAP).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) PT (Completed) GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001599-18 Sponsor Protocol Number: BAY 12-8039/11974 Start Date*: 2006-11-03
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential (intravenous/oral) moxifloxacin 400 mg once daily to intraven...
    Medical condition: complicated skin and skin structure Infections
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040786 Skin structures and soft tissue infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) BE (Completed) LV (Completed) FR (Completed) GR (Completed) IE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001150-15 Sponsor Protocol Number: MD1003CT2015-01-SERENDEM Start Date*: 2016-03-14
    Sponsor Name:MEDDAY PHARMACEUTICALS
    Full Title: SERENDEM study: MD1003 in patients suffering from demyelinating neuropathies, an open label pilot study
    Medical condition: chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating neuropathy associated with immunoglobulin M (IgM) monoclonal gammopathy and antibodies against myelin-associated glycoprotei...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10066137 Anti-MAG neuropathy LLT
    18.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    18.1 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019100-23 Sponsor Protocol Number: BIA-2093-307 Start Date*: 2010-12-02
    Sponsor Name:BIAL – PORTELA & Ca, S.A.
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain
    Medical condition: Diabetic Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002395-24 Sponsor Protocol Number: PM60184-B-001-15 Start Date*: 2015-12-09
    Sponsor Name:Pharma Mar, S.A. , Sociedad Unipersonal
    Full Title: Phase II, Open-Label, Randomized, Controlled Study of PM060184 in Advanced, Hormone Receptor Positive, HER2 negative Breast Cancer Patients in Third or Fourth Line Setting.
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003201-14 Sponsor Protocol Number: ERTUSO Start Date*: 2012-03-02
    Sponsor Name: Krankenhaus Nordwest GmbH
    Full Title: Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-...
    Medical condition: Patients with HER2/neu (1+/SISH positive, 2+ and 3+) expressing solid tumors that are progressing after standard therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002846-21 Sponsor Protocol Number: PARENTIDE-02 Start Date*: 2017-04-10
    Sponsor Name:BCN Peptides S.A.
    Full Title: CLINICAL TRIAL PHASE IIa PROOF OF CONCEPT, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED IN PATIENTS WITH NEUROPATHIC PAIN DUE TO PERIPHERAL NERVE INJURY
    Medical condition: Patients with neuropathic pain due to peripheral nerve injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002023-21 Sponsor Protocol Number: GO39942 Start Date*: 2018-08-31
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB ...
    Medical condition: Diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) PT (Completed) BE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 09:00:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA